Clinical trials: MGD
Meibomian Gland Dysfunction, Blepharitis
Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD
The purpose of this study is to compare the safety and efficacy of TP-03, 0.25%, an eyedrop, BID vs TID dosing regimens for the treatment of meibomian gland dysfunction in patients with Demodex lid infestation.
- Conditions
- Meibomian Gland Dysfunction, Blepharitis, Demodex Infestation
- Trial name
- Ersa (NCT05454956)
- Testing
- TP-03, TP-03 Vehicle
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- Tarsus Pharmaceuticals, Inc.
Meibomian Gland Dysfunction, Dry Eye
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
The study objective is to evaluate the long-term treatment effectiveness for adult patients with meibomian gland dysfunction (MGD) and evaporative dry eye by: 1) comparing the LipiFlow® System to a standardized daily warm…
- Trial name
- NCT01521507
- Testing
- LipiFlow System, Warm Compress Therapy + Lid Scrub
- Where
- 9 sites in United States
- Volunteers
- 200 people
- Sponsor
- TearScience, Inc.
Evaporative Dry Eye
iLux Treatment for Meibomian Gland Dysfunction (MGD)
The purpose of this study is to assess changes in meibomian gland function and evaporative dry eye symptoms after treatment with the iLux medical device.
- Trial name
- NCT03055650
- Testing
- iLux 2020 System
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Tear Film Innovations, Inc.
Meibomian Gland Dysfunction
Methods to Enhance AZR-MD-001 for Meibomian Gland Dysfunction (MGD)
Single-center, single-masked (the individual(s) performing efficacy and safety measures will be masked to treatment assignment for the patient(s) they are assessing), vehicle-controlled, randomized study.
- Trial name
- NCT04314362
- Testing
- AZR-MD-001 ointment/semi-solid drug
- Where
- Australia
- Volunteers
- 32 people
- Sponsor
- Azura Ophthalmics
Meibomian Gland Dysfunction, Evaporative Dry Eye Disease
Comparison Between iLux and LipiFlow in the Treatment of Meibomian Gland Dysfunction (MGD): A 12-month, Multicenter Study
The purpose of this post-approval study is to demonstrate that iLux treatment offers comparable treatment effectiveness to LipiFlow for MGD treatment at 12 months post single treatment.
- Trial name
- NCT03956225
- Testing
- Systane iLux® Dry Eye System, LipiFlow® Thermal Pulsation System
- Where
- 15 sites in United States
- Volunteers
- 299 people
- Sponsor
- Alcon Research
Meibomian Gland Dysfunction
Evaluation of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD)
AZ202001 is a multicenter study of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland Dysfunction (MGD)
- Trial name
- NCT04391959
- Testing
- AZR-MD-001 Active, AZR-MD-001 Vehicle
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 31 people
- Sponsor
- Azura Ophthalmics
Blepharitis, Dry Eye Syndrome
Treatment of Meibomian Gland Dysfunction Prior to Cataract Surgery
The purpose of this pilot feasibility study is to assess whether treating meibomian gland dysfunction (MGD) prior to cataract surgery helps promote meibomian gland function, visual quality and ocular comfort after cataract…
- Trial name
- NCT01808560
- Testing
- LipiFlow Pre-Treatment, LipiFlow Post-treatment
- Where
- 7 sites in United States
- Volunteers
- 34 people
- Sponsor
- TearScience, Inc.
Meibomian Gland Dysfunction (MGD), Contact Lens Discomfort (CLD)
An Evaluation of AZR-MD-001 as Treatment for Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD)
SOVS2019-070 is a single-center study of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD).
- Trial name
- NCT03972501
- Testing
- AZR-MD-001 Vehicle, AZR-MD-001 Active Dose
- Where
- Australia
- Volunteers
- 26 people
- Sponsor
- Azura Ophthalmics
Meibomian Gland Dysfunction, Dry Eye
A Multicenter Study Evaluating AZR-MD-001 in Patients With Meibomian Gland Dysfunction and Evaporative Dry Eye Disease (DED)
AZ201801 is a multicenter study of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland Dysfunction (MGD) and evaporative Dry Eye Disease (DED)
- Trial name
- NCT03652051
- Testing
- AZR-MD-001 Low Dose, AZR-MD-001 Mid Dose, AZR-MD-001 High Dose
- Where
- 30 sites in Australia, Canada and 1 more
- Volunteers
- 321 people
- Sponsor
- Azura Ophthalmics
Cataracts, Meibomian Gland Dysfunction (MGD)
A Post-Market Evaluation of LipiFlow Treatment in Cataract Surgery Practice
This is a post-market, prospective, randomized, multi-center, bilateral, open-label, cross-over, comparative clinical study. Study group will undergo preoperative LipiFlow treatment and Control group will not receive preoperative…
- Trial name
- NCT03708367
- Testing
- LipiFlow Thermal Pulsation System
- Where
- 5 sites in United States
- Volunteers
- 117 people
- Sponsor
- Johnson & Johnson Surgical Vision, Inc.